85
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Altered miRNA expression in aniline-mediated cell cycle progression in rat spleen

, &
Pages 511-517 | Received 23 Feb 2017, Accepted 26 Apr 2017, Published online: 06 Jun 2017

References

  • Abukhdeir AM, Park BH. 2008. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med. 10:1–18.
  • Bhushan L, Kandpal RP. 2011. EphB6 receptor modulates micro RNA profile of breast carcinoma cells. PLoS One. 6:e22484.
  • Bueno MJ, Malumbres M. 2011. MicroRNAs and the cell cycle. Biochim Biophys Acta. 1812:592–601.
  • Bus JS, Popp JA. 1987. Perspectives on the mechanism of action of the splenic toxicity of aniline and structurally-related compounds. Food Chem Toxicol. 25:619–626.
  • Cannell IG, Kong YW, Johnston SJ, Chen ML, Collins HM, Dobbyn HC, Elia A, Kress TR, Dickens M, Clemens MJ, et al. 2010. p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication. Proc Natl Acad Sci USA. 107:5375–5380.
  • Chafin CB, Regna NL, Caudell DL, Reilly CM. 2014. MicroRNA-let-7a promotes E2F-mediated cell proliferation and NFκB activation in vitro. Cell Mol Immunol. 11:79–93.
  • Chulu JL, Liu HJ. 2009. Recent patents on cell cycle regulatory proteins. Recent Pat Biotechnol. 3:1–9.
  • Cuesta R, Martínez-Sánchez A, Gebauer F. 2009. miR-181a regulates cap-dependent translation of p27(kip1) mRNA in myeloid cells. Mol Cell Biol. 29:2841–2851.
  • Di Girolamo F, Campanella L, Samperi R, Bachi A. 2009. Mass spectrometric identification of hemoglobin modifications induced by nitrosobenzene. Ecotoxicol Environ Saf. 72:1601–1608.
  • Di Leva G, Garofalo M, Croce CM. 2014. MicroRNAs in cancer. Annu Rev Pathol. 9:287–314.
  • Garo LP, Murugaiyan G. 2016. Contribution of MicroRNAs to autoimmune diseases. Cell Mol Life Sci. 73:2041–2051.
  • Giacinti C, Giordano A. 2006. RB and cell cycle progression. Oncogene. 25:5220–5227.
  • Goodman DG, Ward JM, Reichardt WD. 1984. Splenic fibrosis and sarcomas in F344 rats fed diets containing aniline hydrochloride, p-chloroaniline, azobenzene, o- toluidine hydrochloride, 4,4'-sulfonyldianiline, or D & C red No. 9. J Natl Cancer Inst. 73:265–273.
  • Esquela-Kerscher A, Slack FJ. 2006. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269.
  • Jansson MD, Lund AH. 2012. MicroRNA and cancer. Mol Oncol. 6:590–610.
  • Khan MF, Boor PJ, Gu Y, Alcock NW, Ansari GAS. 1997. Oxidative stress in the splenotoxicity of aniline. Fundam Appl Toxicol. 35:22–30.
  • Khan MF, Wu X, Alcock NW, Boor PJ, Ansari GAS. 1999. Iron exacerbates aniline-associated splenic toxicity. J Toxicol Environ Health Part A. 57:173–184.
  • Khan MF, Wu X, Wang J. 2003. Up-regulation of transforming growth factor-beta 1 in the spleen of aniline-treated rats. Toxicol Appl Pharmacol. 187:22–28.
  • Khan MF, Kannan S, Wang J. 2006. Activation of transcription factor AP-1 and mitogen-activated protein kinases in aniline-induced splenic toxicity. Toxicol Appl Pharmacol. 210:86–93.
  • Lal A, Navarro F, Maher CA, Maliszewski LE, Yan N, O’Day E, Chowdhury D, Dykxhoorn DM, Tsai P, Hofmann O, et al. 2009. miR-24 inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to “seedless” 3'UTR microRNA recognition elements. Mol Cell. 35:610–625.
  • Li C, Gao Y, Zhang K, Chen J, Han S, Feng B, Wang R, Chen L. 2015. Multiple roles of microRNA-100 in human cancer and its therapeutic potential. Cell Physiol Biochem. 37:2143–2159.
  • Li J, You T, Jing J. 2014. MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway. Cell Prolif. 47:152–160.
  • Ma H, Wang J, Abdel-Rahman SZ, Boor PJ, Khan MF. 2008. Oxidative DNA damage and its repair in rat spleen following subchronic exposure to aniline. Toxicol Appl Pharmacol. 233:247–253.
  • Ma H, Wang J, Abdel-Rahman SZ, Hazra TK, Boor PJ, Khan MF. 2011. Induction of NEIL1 and NEIL2 DNA glycosylases in aniline-induced splenic toxicity. Toxicol Appl Pharmacol. 251:1–7.
  • Malumbres M, Barbacid M. 2001. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 1:222–231.
  • Malumbres M, Barbacid M. 2009. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 9:153–166.
  • Menon SG, Sarsour EH, Kalen AL, Venkataraman S, Hitchler MJ, Domann FE, Oberley LW, Goswami PC. 2007. Superoxide signaling mediates N-acetyl- L-cysteine-induced G1 arrest: regulatory role of cyclin D1 and manganese superoxide dismutase. Cancer Res. 67:6392–6399.
  • Petrelli A, Perra A, Schernhuber K, Cargnelutti M, Salvi A, Migliore C, Ghiso E, Benetti A, Barlati S, Ledda-Columbano GM, et al. 2012. Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene. 31:4517–4526.
  • Ravegnini G, Sammarini G, Hrelia P, Angelini S. 2015. Key Genetic and Epigenetic mechanisms in Chemical Carcinogenesis. Toxicol Sci. 148:2–13.
  • Shen T, Huang S. 2012. The role of Cdc25A in the regulation of cell proliferation and apoptosis. Anticancer Agents Med Chem. 12:631–639.
  • Stark GR, Taylor WR. 2006. Control of the G2/M transition. Mol Biotechnol. 32:227–248.
  • Sur S, Agrawal DK. 2016. Phosphatases and kinases regulating CDC25 activity in the cell cycle: clinical implications of CDC25 overexpression and potential treatment strategies. Mol Cell Biochem. 416:33–46.
  • Svoronos AA, Engelman DM, Slack FJ. 2016. OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer. Cancer Res. 76:3666–3670.
  • Tan G, Niu J, Shi Y, Ouyang H, Wu ZH. 2012. NF-κB-dependent microRNA- 125b up-regulation promotes cell survival by targeting p38α upon ultraviolet radiation. J Biol Chem. 287:33036–33047.
  • VanArsdale T, Boshoff C, Arndt KT, Abraham RT. 2015. Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment. Clin Cancer Res. 21:2905–2910.
  • Wang J, Kannan S, Li H, Khan MF. 2005. Cytokine gene expression and activation of NF-kappa B in aniline-induced splenic toxicity. Toxicol Appl Pharmacol. 203:36–44.
  • Wang J, Wang G, Ansari GAS, Khan MF. 2008. Activation of oxidative stress- responsive signaling pathways in early splenotoxic response of aniline. Toxicol Appl Pharmacol. 230:227–234.
  • Wang J, Ma H, Boor PJ, Ramanujam VM, Ansari GA, Khan MF. 2010. Up- regulation of heme oxygenase-1 in rat spleen after aniline exposure. Free Radic Biol Med. 48:513–518.
  • Wang J, Wang G, Ma H, Khan MF. 2011. Enhanced expression of cyclins and cyclin-dependent kinases in aniline-induced cell proliferation in rat spleen. Toxicol Appl Pharmacol. 250:213–220.
  • Wang J, Wang G, Khan MF. 2015. Disorder of G2-M checkpoint control in aniline-induced cell proliferation in rat spleen. PLoS One. 10:e0131457.
  • Weinberger MA, Albert RH, Montgomery SB. 1985. Splenotoxicity associated with splenic sarcomas in rats fed high doses of D & C Red No. 9 or aniline hydrochloride. J Natl Cancer Inst. 75:681–690.
  • Williams GH, Stoeber K. 2012. The cell cycle and cancer. J Pathol. 226:352–364.
  • Wolgemuth DJ, Manterola M, Vasileva A. 2013. Role of cyclins in controlling progression of mammalian spermatogenesis. Int J Dev Biol. 57:159–168.
  • Wu X, Kannan S, Ramanujam VM, Khan MF. 2005. Iron release and oxidative DNA damage in splenic toxicity of aniline. J Toxicol Environ Health A. 68:657–666.
  • Zhao LL, Jin F, Ye X, Zhu L, Yang JS, Yang WJ. 2015. Expression profiles of miRNAs and involvement of miR-100 and miR-34 in regulation of cell cycle arrest in Artemia. Biochem J. 470:223–231.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.